Pharmacists can improve cardiometabolic adherence by easing adverse effects, simplifying regimens, tackling costs, and synchronizing refills.

First approved for adults in 2022, the therapy is now cleared for adults and pediatric patients weighing 66 lbs or more with symptomatic obstructive hypertrophic cardiomyopathy.

Researchers outline individual peripheral arterial disease burden as well as the most at-risk patient populations and treatment recommendations.

Study findings tie continuous glucose monitoring measures to elevated cardiovascular risk in adults without diabetes.

An American Heart Association scientific statement shows earlier risk factors and social barriers driving cardiovascular disparities in Hispanic adults.

Pharmacist pain clinics typically focus on comprehensive medication management involving the entire patient scenario.

A case shows a suspected recurrence of pneumococcal disease that ended with removal of one cochlear implant and replacement of the other.

Detailed phase 3 data show retatrutide lowered body weight and A1C over 80 weeks for patients with diabetes and obesity.